CSBio CSBio

X
[{"orgOrder":0,"company":"Sanofi","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Begins Dosing of DNL758 in Phase Ib Covid-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell Initiates the First Clinical Trial of its Covid-19 \n Prevention Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"MedinCell"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Conducted by MedinCell Confirms the Safety of Continuous Administration of Ivermectin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"MedinCell"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of CoVepiT","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Cenexi","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Cenexi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, its Multi-Target T-cell Anti-COVID Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"LinKinVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LinKinVax Welcomes Interim Results of the ANRS VRI06 Phase I Trial Evaluating a Novel HIV Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"LinKinVax"},{"orgOrder":0,"company":"Antabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Antabio"},{"orgOrder":0,"company":"4P-Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"4Living Biotech and Sanofi Enter into a Collaboration Agreement to Demonstrate Potential Clinical Efficacy of Mozobil\u00ae as a Treatment for Acute and Chronic Complications of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"4P-Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Sanofi and Translate Bio have developed and will evaluate two formulations of the vaccine (MRT5400 and MRT5401) in the Phase 1 influenza mRNA vaccine clinical trial. The two formulations differ in the lipid nanoparticle (LNP) that contains the mRNA.

            Lead Product(s): mRNA-based Flu Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: MRT5400

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2021

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            Sanofi and Translate Bio have developed and will evaluate two formulations of the vaccine (MRT5400 and MRT5401) in the Phase 1 influenza mRNA vaccine clinical trial. The two formulations differ in the lipid nanoparticle (LNP) that contains the mRNA.

            Lead Product(s): MRT5400

            Therapeutic Area: Infections and Infectious Diseases Product Name: MRT5400

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2021

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            Dosing of DNL758 has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19.

            Lead Product(s): DNL758

            Therapeutic Area: Infections and Infectious Diseases Product Name: SAR443122

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Denali Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 30, 2020

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            MEM-ANT3310 combines the well-known carbapenem meropenem (MEM) with ANT3310, a breakthrough serine-beta-lactamase (SBL) inhibitor.

            Lead Product(s): ANT3310,Meropenem

            Therapeutic Area: Infections and Infectious Diseases Product Name: MEM-ANT3310

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 25, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The CD40.HIVRI.Env vaccine candidate is developed by the VRI that targets an immune response binding HIV envelope protein to monoclonal antibodies specifically targeting CD40 receptors on the surface of dendritic cells.

            Lead Product(s): CD40.HIVRI.Env,Poly-ICLC

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Positive analysis of long-term immune T cell responses of CoVepiT, its prophylactic vaccine candidate against COVID-19, with positive immunological results obtained at 6 months on T cell memory response in the vaccinated subjects.

            Lead Product(s): CoVepiT

            Therapeutic Area: Infections and Infectious Diseases Product Name: CoVepiT

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            New clinical data confirm the good tolerance of CoVepiT, with good immunogenicity of the T cells against the viral epitopes in healthy volunteers vaccinated.

            Lead Product(s): CoVepiT

            Therapeutic Area: Infections and Infectious Diseases Product Name: CoVepiT

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration aims to to demonstrate the potential efficacy of Mozobil (plerixafor) in blocking CXCR4 receptor for the treatment of acute and long-lasting complications of COVID-19 in a Phase 2 global clinical trial.

            Lead Product(s): Plerixafor

            Therapeutic Area: Infections and Infectious Diseases Product Name: Mozobil

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 23, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Cenexi will manufacture and process the peptides, produce the sterile emulsion and package the clinical batches of CoVepiT being used in the ongoing Phase 1 clinical trial and potentially for further clinical phases, subject to positive results of the Phase 1.

            Lead Product(s): CoVepiT

            Therapeutic Area: Infections and Infectious Diseases Product Name: OSE13E

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: OSE Immunotherapeutics SA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This phase 1 clinical trial is evaluating the safety, reactogenicity and immunogenicity of two dose regimen of CoVepiT in 48 healthy adult volunteers, previously vaccinated or not by an authorized Covid-19 vaccine.

            Lead Product(s): CoVepiT

            Therapeutic Area: Infections and Infectious Diseases Product Name: OSE13E

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 26, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY